Hydroxychloroquine Suppresses Interferon-inducible Genes and B Cell Activating Factor in Patients With Incomplete and New-onset Systemic Lupus Erythematosus

REFERENCES

1. 1.↵
   1. Segura BT,
   2. Bernstein BS,
   3. McDonnell T,
   4. Wincup C,
   5. Ripoll V,
   6. Giles I, et al.

   Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort. Rheumatology 2020;59:524-33.

   OpenUrlPubMed
2. 2.↵
   1. Petri M,
   2. Orbai AM,
   3. Alarcõn GS,
   4. Gordon C,
   5. Merrill JT,
   6. Fortin PR, et al.

   Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677-86.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Hochberg MC.

   Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Aringer M,
   2. Costenbader K,
   3. Daikh D,
   4. Brinks R,
   5. Mosca M,
   6. Ramsey-Goldman R, et al.

   2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 2019;78:1151-9.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Ruiz-Irastorza G,
   2. Ramos-Casals M,
   3. Brito-Zeron P,
   4. Khamashta MA.

   Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010;69:20–8.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. James JA,
   2. Kim-Howard XR,
   3. Bruner BF,
   4. Jonsson MK,
   5. McClain MT,
   6. Arbuckle MR, et al.

   Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus 2007;16:401-9.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Stahl Hallengren C,
   2. Nived O,
   3. Sturfelt G.

   Outcome of incomplete systemic lupus erythematosus after 10 years. Lupus 2004; 13: 85-8.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Kirou KA,
   2. Lee C,
   3. George S,
   4. Louca K,
   5. Papagiannis IG,
   6. Peterson MGE, et al.

   Coordinate overexpression of interferon-α-induced genes in systemic lupus erythematosus. Arthritis Rheum 2004;50:3958-67.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Md Yusof MY,
   2. Psarras A,
   3. El-Sherbiny YM,
   4. Hensor EMA,
   5. Dutton K,
   6. Ul-Hassan S, et al.

   Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status. Ann Rheum Dis 2018;77:1432-9.

   OpenUrl
10. 10.↵
    1. Munroe ME,
    2. Lu R,
    3. Zhao YD,
    4. Fife DA,
    5. Robertson JM,
    6. Guthridge JM, et al.

    Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann Rheum Dis 2016;75:2014-21.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Gladman DD,
    2. Ibañez D,
    3. Urowitz MB.

    Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 2002;29:288-91.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Lambers WM,
    2. de Leeuw K,
    3. Doornbos-van der Meer B,
    4. Diercks GFH,
    5. Bootsma H,
    6. Westra J.

    Interferon score is increased in incomplete systemic lupus erythematosus and correlates with myxovirus-resistance protein A in blood and skin. Arthritis Res Ther 2019;21:260.

    OpenUrl
13. 13.↵
    1. Willis R,
    2. Seif AM,
    3. McGwin G,
    4. Martinez-Martinez LA,
    5. González EB,
    6. Dang N, et al.

    Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort. Lupus 2012;21:830-5.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Olsen NJ,
    2. McAloose C,
    3. Carter J,
    4. Han BK,
    5. Raman I,
    6. Li Q-Z, et al.

    Clinical and immunologic profiles in incomplete lupus erythematosus and improvement with hydroxychloroquine treatment. Autoimmune Dis 2016;2016:8791629.

    OpenUrl
15. 15.↵
    1. Hernández-Breijo B,
    2. Gomez A,
    3. Soukka S,
    4. Johansson P,
    5. Parodis I.

    Antimalarial agents diminish while methotrexate, azathioprine and mycophenolic acid increase BAFF levels in systemic lupus erythematosus. Autoimmun Rev 2019;18:102372.

    OpenUrl
16. 16.↵
    1. Munroe ME,
    2. Young KA,
    3. Kamen DL,
    4. Guthridge JM,
    5. Niewold TB,
    6. Costenbader KH, et al.

    Discerning risk of disease transition in relatives of systemic lupus erythematosus patients utilizing soluble mediators and clinical features. Arthritis Rheumatol 2017; 69:630-42.

    OpenUrl